Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Transcenta Holding Limited ( (HK:6628) ) is now available.
Transcenta reported that revenue fell to RMB7.4 million in 2025 from RMB11.3 million a year earlier, mainly due to lower CDMO service income, while other income also declined on reduced interest earnings. However, research and development as well as administrative and selling expenses were significantly cut through pipeline advancement and resource prioritization, narrowing total comprehensive loss to RMB198.3 million from RMB294.3 million.
On a non-IFRS basis, the company saw R&D and administrative costs excluding share-based payments drop materially, leading to an adjusted comprehensive loss reduction to RMB190.0 million from RMB270.4 million. These shifts indicate a strategic focus on cost discipline and portfolio optimization, which, despite weaker revenue, has improved loss metrics and may support more sustainable operations and investor confidence if maintained.
The most recent analyst rating on (HK:6628) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Transcenta Holding Limited stock, see the HK:6628 Stock Forecast page.
More about Transcenta Holding Limited
Transcenta Holding Limited is a biotechnology company focused on developing innovative biopharmaceuticals, with revenue contributions that include contract development and manufacturing organization (CDMO) services. The group invests heavily in research and development to advance its therapeutic pipeline while operating out of the Cayman Islands as a listed entity in Hong Kong, targeting growth in the biopharma sector.
Average Trading Volume: 924,577
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.13B
See more data about 6628 stock on TipRanks’ Stock Analysis page.